全文获取类型
收费全文 | 24259篇 |
免费 | 6158篇 |
国内免费 | 150篇 |
专业分类
耳鼻咽喉 | 648篇 |
儿科学 | 738篇 |
妇产科学 | 749篇 |
基础医学 | 704篇 |
口腔科学 | 2714篇 |
临床医学 | 4593篇 |
内科学 | 5631篇 |
皮肤病学 | 519篇 |
神经病学 | 2263篇 |
特种医学 | 1078篇 |
外科学 | 4140篇 |
综合类 | 80篇 |
现状与发展 | 12篇 |
一般理论 | 1篇 |
预防医学 | 3146篇 |
眼科学 | 338篇 |
药学 | 438篇 |
中国医学 | 6篇 |
肿瘤学 | 2769篇 |
出版年
2024年 | 167篇 |
2023年 | 1124篇 |
2022年 | 414篇 |
2021年 | 734篇 |
2020年 | 1275篇 |
2019年 | 600篇 |
2018年 | 1426篇 |
2017年 | 1367篇 |
2016年 | 1572篇 |
2015年 | 1641篇 |
2014年 | 2073篇 |
2013年 | 2534篇 |
2012年 | 996篇 |
2011年 | 914篇 |
2010年 | 1436篇 |
2009年 | 2008篇 |
2008年 | 881篇 |
2007年 | 613篇 |
2006年 | 776篇 |
2005年 | 553篇 |
2004年 | 440篇 |
2003年 | 391篇 |
2002年 | 362篇 |
2001年 | 448篇 |
2000年 | 323篇 |
1999年 | 440篇 |
1998年 | 534篇 |
1997年 | 511篇 |
1996年 | 564篇 |
1995年 | 414篇 |
1994年 | 323篇 |
1993年 | 280篇 |
1992年 | 225篇 |
1991年 | 204篇 |
1990年 | 174篇 |
1989年 | 170篇 |
1988年 | 152篇 |
1987年 | 166篇 |
1986年 | 125篇 |
1985年 | 115篇 |
1984年 | 102篇 |
1983年 | 108篇 |
1982年 | 113篇 |
1981年 | 84篇 |
1980年 | 69篇 |
1979年 | 59篇 |
1978年 | 68篇 |
1977年 | 59篇 |
1975年 | 54篇 |
1974年 | 57篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Maaike van Gerwen MD Naomi Alpert MS Raja Flores MD Emanuela Taioli MD PhD 《American journal of industrial medicine》2020,63(2):115-120
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of national agencies. This review compares currently existing mesothelioma registries worldwide to develop a concept model for a US real-time case capture mesothelioma registry. Five countries were identified with a mesothelioma specific registry, including Italy, France, UK, Australia, and South Korea. All, except the UK, used interviews to collect exposure data. Linkage with the national death index was available or was in future plans for all registries. The registries have limited information on treatment, quality of life, and other patient-centered outcomes such as symptoms and pain management. To thoroughly collect exposure data, “real-time” enrollment is preferable; to maximize the capture of mesothelioma cases, optimal coverage, and a simplified consent process are needed. 相似文献
4.
Chie Teramoto PHN RN MS Satoko Nagata PhD PHN RN Reiko Okamoto PhD PHN RN Ruriko Suzuki PHN RN MS Emiko Kishi PhD PHN RN Michie Nomura DSN PHN RN Noriko Jojima PHN RN MS Masumi Nishida PhD PHN RN Keiko Koide PhD PHN RN Emiko Kusano PhD PHN RN Saori Iwamoto PhD PHN RN Sachiyo Murashima PhD PHN RN 《Public health nursing (Boston, Mass.)》2015,32(6):654-661
5.
6.
Catherine L. Omosule Dominique Joseph Brooke Weiler Victoria L. Gremminger Spencer Silvey Youngjae Jeong Ashique Rafique Pamela Krueger Sandra Kleiner Charlotte L. Phillips 《Journal of bone and mineral research》2022,37(5):938-953
Osteogenesis imperfecta (OI) is a collagen-related bone disorder characterized by fragile osteopenic bone and muscle weakness. We have previously shown that the soluble activin receptor type IIB decoy (sActRIIB) molecule increases muscle mass and improves bone strength in the mild to moderate G610C mouse model of OI. The sActRIIB molecule binds multiple transforming growth factor-β (TGF-β) ligands, including myostatin and activin A. Here, we investigate the musculoskeletal effects of inhibiting activin A alone, myostatin alone, or both myostatin and activin A in wild-type (Wt) and heterozygous G610C (+/G610C) mice using specific monoclonal antibodies. Male and female Wt and +/G610C mice were treated twice weekly with intraperitoneal injections of monoclonal control antibody (Ctrl-Ab, Regn1945), anti-activin A antibody (ActA-Ab, Regn2476), anti-myostatin antibody (Mstn-Ab, Regn647), or both ActA-Ab and Mstn-Ab (Combo, Regn2476, and Regn647) from 5 to 16 weeks of age. Prior to euthanasia, whole body composition, metabolism and muscle force generation assessments were performed. Post euthanasia, hindlimb muscles were evaluated for mass, and femurs were evaluated for changes in microarchitecture and biomechanical strength using micro–computed tomography (μCT) and three-point bend analyses. ActA-Ab treatment minimally impacted the +/G610C musculoskeleton, and was detrimental to bone strength in male +/G610C mice. Mstn-Ab treatment, as previously reported, resulted in substantial increases in hindlimb muscle weights and overall body weights in Wt and male +/G610C mice, but had minimal skeletal impact in +/G610C mice. Conversely, the Combo treatment outperformed ActA-Ab alone or Mstn-Ab alone, consistently increasing hindlimb muscle and body weights regardless of sex or genotype and improving bone microarchitecture and strength in both male and female +/G610C and Wt mice. Combinatorial inhibition of activin A and myostatin more potently increased muscle mass and bone microarchitecture and strength than either antibody alone, recapturing most of the observed benefits of sActRIIB treatment in +/G610C mice. © 2022 American Society for Bone and Mineral Research (ASBMR). 相似文献
7.
8.
Oliver Sartor MD Daniel Heinrich MD Neil Mariados MD Maria José Méndez Vidal MD Daniel Keizman MD Camilla Thellenberg Karlsson MD Avivit Peer MD Giuseppe Procopio MD Stephen J. Frank MD Kalevi Pulkkanen MD Eli Rosenbaum MD Stefano Severi MD José Trigo MD Lucia Trandafir MD Volker Wagner MD Rui Li MS Luke T. Nordquist MD 《The Prostate》2019,79(14):1683-1691
9.
10.